Related Experiment Video
Updated: May 14, 2026
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
Potential Biomarkers of Therapeutic Response to ECP in Solid Organ Transplantation
Hendrik Veltman1,2, Eva Martinez-Caceres1,2,3, Maria Iglesias-Escudero1,2,3
1Immunopathology Laboratory, Germans Trias I Pujol Research Institute, Badalona, Catalonia, Spain.
Abstract:
One of the major hurdles in solid organ transplantation is graft rejection, which must be prevented with lifelong general immunosuppression. However, modern maintenance immunosuppression is accompanied by serious side effects, such as an increased risk of infection and malignancies. The search for alternative therapies specifically controlling allogeneic responses is fueling renewed interest in extracorporeal photopheresis (ECP). Despite guideline indications for ECP in cardiothoracic transplantation, potential applications in liver and kidney transplantation have not been adequately investigated. Presently, limited understanding of the pharmacodynamic effects of ECP and lack of consensus biomarkers are hindering the development of standardized multiparametric assays to assess patient responses. This review explores current knowledge about immune responses after ECP in transplant recipients and collates a set of biomarkers associated with favorable treatment responses.
Insights
Extracorporeal photopheresis (ECP) shows promise for managing transplant rejection and reducing immunosuppression side effects. Further research into its immune effects and biomarkers is needed for broader application in organ transplantation.
Area of Science:
- Immunology
- Transplantation Medicine
- Medical Technology
Background:
- Solid organ transplantation faces challenges with graft rejection, necessitating lifelong immunosuppression.
- Current immunosuppression carries risks like infection and malignancy.
- Extracorporeal photopheresis (ECP) is being re-evaluated as an alternative therapy.
Purpose of the Study:
- To review current knowledge on immune responses following ECP in transplant recipients.
- To identify potential biomarkers associated with positive ECP treatment outcomes.
- To explore ECP's applicability beyond cardiothoracic transplantation, particularly in liver and kidney recipients.
Main Methods:
- Literature review of studies on ECP and immune responses in transplant patients.
- Analysis of existing data on pharmacodynamic effects of ECP.
- Collating and evaluating potential biomarkers for ECP efficacy.
Main Results:
- ECP is indicated for cardiothoracic transplantation but under-investigated in liver and kidney transplantation.
- Limited understanding of ECP's pharmacodynamic effects and lack of consensus biomarkers hinder assay development.
- A set of biomarkers linked to favorable ECP responses has been identified.
Conclusions:
- ECP presents a potential alternative to general immunosuppression in transplantation.
- Further research is required to elucidate ECP's mechanisms and standardize its application.
- Identifying and validating biomarkers is crucial for optimizing ECP therapy and assessing patient response.
